Keryx Biopharmaceuticals — Q3 2016 Earnings Presentation
17 slides from Keryx Biopharmaceuticals's earnings presentation, Nov 9, 2016
Slide 1: Third Quarter 2016 Financial Results Conference Call
Third Quarter 2016 Financial Results Conference Call November 9, 2016 Keryx Biopharmaceuticals, Inc. Exhibit 99.2
Slide 2: Safe Harbor Statement
Safe Harbor Statement Some of the statements included in this presentation, particularly those regarding future revenues and expenses and the commercialization and ongoing clinical development of Auryxia, including those statements related to the interruption in the supply of Auryxia and when Auryxi
Slide 3: Third Quarter 2016 Financial Results - Agenda
Third Quarter 2016 Financial Results - Agenda Topic Speaker Introduction Amy Sullivan, VP Strategic Operations and Corporate Affairs Opening Remarks Greg Madison, President and CEO Third Quarter Financial Results Scott Holmes, Chief Financial Officer sNDA submission and ASN 2016 John Neylan, M.D., C
Slide 4: Business Focus Past Three Months
Business Focus Past Three Months Managed through temporary supply interruption Ready to make Auryxia available pending FDA approval of second manufacturer Completed sNDA to expand Auryxia’s label for potential treatment of iron deficiency anemia in adults with stage 3-5 NDD-CKD Ready to submit sNDA
Slide 5: Auryxia Contract Manufacturers
Production-related issue converting API to finished drug product Does not affect safety profile of currently available Auryxia Working with two contract manufacturers to restore supply CMO1 Identified step in process where issue is occurring Working together to resolve issue and resume production CM
Slide 6: Financial Highlights
Financial Highlights Scott Holmes Chief Financial Officer
Slide 7: Third Quarter 2016 Financial Highlights
Third Quarter 2016 Financial Highlights ($ in thousands) Three Months Ended September 30, 2016 (unaudited) Three Months Ended September 30, 2015 (unaudited) Auryxia Net U.S. Product Sales $5,050 $3,191 License Revenue $1,287 $1,017 Total Revenue $6,337 $4,208 Cost of Goods Sold* $18,196 $3,065 SG&A
Slide 8: sNDA for Potential Label Expansion & ASN 2016
sNDA for Potential Label Expansion & ASN 2016 John Neylan, M.D. Chief Medical Officer
Slide 9: Potential Label Expansion of Auryxia
Potential Label Expansion of Auryxia Anemia Management Phase 3 study for IDA in adults with stage 3-5 NDD-CKD demonstrated statistically significant differences between the ferric citrate and placebo groups for the primary and all pre-specified secondary endpoints sNDA complete; ready to submit appl
Slide 10: Auryxia ASN Kidney Week Poster Presentations
Auryxia® (ferric citrate) ASN Kidney Week Poster Presentations Poster Title Author Date/Time/Location Effects of ferric citrate in adults with non-dialysis dependent chronic kidney disease and iron-deficiency anemia: Phase 3 trial Steven Fishbane, M.D. Thursday, November 17 9:30 a.m. – 2:30 p.m. Pos
Slide 11: Auryxia Return to Patients
Auryxia Return to Patients Doug Jermasek V.P. Marketing and Strategy
Slide 12: Renal Community Support
Renal Community Support
Slide 13: Commercial Readiness for Auryxia Resupply
Three types of patients upon resupply: Patients who have been switched to another binder Patients who have been maintained on Auryxia New patients who could benefit from Auryxia treatment Market research suggests: Physicians and dietitians who have had patients on Auryxia have a willingness to retur
Slide 14: How We View the CKD Market in the U.S.
How We View the CKD Market in the U.S. Sources: http://www.kidney.org/kidneydisease; U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive an
Slide 15: Closing Remarks and Q&A
Closing Remarks and Q&A
Slide 16: Key Takeaways
Key Takeaways Supply of Auryxia rebuilt; prepared to make Auryxia available to people on dialysis, pending FDA approval of Patheon Completed sNDA for potential label expansion of Auryxia; ready to submit application pending FDA agreement on pediatric plan Presenting more detailed IDA/CKD Phase 3 dat
Slide 17: Third Quarter 2016 Financial Results Conference Call
Third Quarter 2016 Financial Results Conference Call November 9, 2016 Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals — Q3 2016 Earnings Presentation on 6ix